For many years, vaccines for preventing infectious diseases have been a key public health intervention. This technology has increased the incidence rate and mortality of the global population by protecting the global population from many life-threatening diseases. During the pandemic, the challenges are high as teams around the world must work hard for years to develop a safe and effective COVID-19 vaccine. In such a busy period, having a fast, reliable, and stable tool to monitor the host's immune response after vaccination is crucial. Quantitative ELISA achieves this goal with its simple yet highly flexible immunoassay technique. Quantitative ELISA provides countless solutions for vaccine quality control analysis and is also an important component of vaccine research.
Assessment of Immune Response to Vaccination: An important aspect of vaccination research is the assessment of immune responses utilizing quantitative ELISA. Through the measurement of specific antibodies' concentrations, vaccines capable of engendering protective immune responses can be ascertained. For instance, with the mRNA vaccines BNT162b2 and mRNA-1273, their effectiveness in vaccination was evaluated by monitoring anti-Spike protein antibody levels using quantitative ELISA. Studies have confirmed that these vaccines demonstrate robust induction of high titer antibody response which confers protection against SARS-CoV-2 infection.
Assessment Of Vaccine Effectiveness: The quantitative ELISA also aids in tracking changes in immune responses over periods which proves crucial for long-term vaccine investigations and evaluation of booster doses. This was the case for Typhoid Conjugate Vaccine (TCV) where anti-IgG response to a single vaccine dose among children from Hyderabad, Pakistan was assessed through quantitative ELISA. The findings indicated that very strong immune responses were generated, with responder rates surpassing 80% Therefore this information could help assess how long immunity will last and whether booster doses are necessary or not.
Assessment of Vaccine Formulation and Stability: One of the most important uses of quantitative ELISA in vaccine development is assessment of vaccine formulation and stability. In the case of mRNA vaccines, residual double-stranded RNA (dsRNA) presents some concerns because it can elicit immune responses or other unwanted effects. A sandwich ELISA for dsRNA has been developed to measure residual dsRNA in mRNA vaccine samples from crude IVT reaction mixtures to fully purified bulk drug formulations. This guarantees safety and stability of the final product.
Antibody Detection: ELISA is the gold standard method for detecting antibodies within serum or other biological fluids. In vaccine research, it is used widely for measuring levels of specific antibodies response post vaccination. This includes identifying antibodies against several components of the vaccine which include surface proteins of a virus or toxins from bacteria. Determining antibody titers at intervals provides valuable insights regarding immune memory durability over time.
Isotyping of Antibodies: Different antibody isotypes such as IgG, IgM, IgA etc., all have different roles within an immune system thus with ELISA one can estimate Quantify type define modular units easily ascertain levels utilizing modular unit quantification metric thus can perform accurate measurement. The early appearance of IgM antibodies after vaccination indicates the presence of an initial immune response, while over time, the development of IgG antibodies reflects a more mature and persistent immune response.
The versatility of ELISA makes it a cornerstone technology across the vaccine development pipeline:
Adjuvant evaluation: The safety and immune efficacy evaluation of adjuvants is used to assess the safety and efficacy of adjuvants during vaccine administration or when used alone methods and indicators of immune efficacy. Adding adjuvants to stimulate stronger immune responses in vaccines. The impact of various adjuvants on immune response can be determined through ELISA assay.
Antigen characteristics: ELISA can be used to analyze the purity and concentration of vaccine antigens. By coating the microplate with specific antibodies against the target antigen, it is possible to determine the amount of antigen present in the sample. This information is crucial for ensuring that vaccine formulations contain appropriate amounts of active antigens to induce desired immune responses.
Vaccine efficacy testing: To ensure that vaccines are effective, efficacy testing needs to be conducted. ELISA can be used to compare the immunostimulatory ability of different batches of vaccines. ELISA can be used to measure antibody titers or other immune related parameters in individual or animal samples given different vaccine batches to make sure these batches all meet the requirements for efficacy.
High Sensitivity and Specificity
ELISA can detect very low levels of antibodies or antigens, typically in the picogram to nanogram range, while minimizing cross reactivity with non-target molecules. This makes them highly suitable for detecting even subtle immune reactions or low abundance antigens.
Quantitative Results
Unlike qualitative testing, ELISA provides numerical data on the concentration of the target analyte. This allows for robust statistical analysis and comparison between groups.
High Throughput
The 96 well microplate format allows for simultaneous processing of a large number of samples, making ELISA a high-throughput detection. Automatic plate readers and liquid processing systems can further increase the number of samples that can be processed within a given time.
Our quantitative ELISA kit series is optimized to support vaccine testing throughout the entire product lifecycle. Our solutions feature advanced detection chemistry and our proprietary antibody pairs are selected for excellent sensitivity and extremely low cross reactivity to help ensure reliable data even in the most challenging sample types. Our main products are as follows:
| ELISA Kit | Application |
| Antibody to HBsAg ELISA Kit | This anti-HBs ELISA kit is an enzyme linked immunosorbent assay for quantitative detection of antibodies to hepatitis B virus surface antigen (anti-HBs) in human serum or plasma and assessing antibody response levels to HBsAg-vaccine. |
| Human Papilloma Virus IgG ELISA kit | Enzyme Immuno Assay (EIA) for determination of IgG class antibodies to Human Papilloma Virus (or HPV) in human plasma and sera. The product is supplied for research purpose only. It is not for use in the diagnosis or for the follow-up of patients administered with the vaccines containing HPV antigens. |
| HHV-6 IgG ELISA Kit | For the detection of IgG antibodies to HHV-6 in human serum isolated from venous or capillary blood. |
| Human Haemophilus Influenza B IgG ELISA Kit | Enzyme immunoassay for the determination of IgG antibodies against polyribosylribitolphosphate (PRP) of Haemophilus influenzae type B in human serum and plasma. |
| SARS Coronavirus IgG ELISA Kit | For the qualitative determination of IgG class antibodies against SARS Coronavirus in Human serum or plasma. It is intended for diagnosing and monitoring of patients related to infection by SARS Coronavirus. |
| Human Tetanus Toxoid IgG ELISA Kit | The ELISA test kit provides a quantitative in vitro assay for human antibodies of the immunoglobulin class IgG against tetanus toxoid in serum or plasma for the clarification of an unclear immune status. |
ELISA is an essential tool in vaccine research, development, and quality control. It can generate sensitive, specific, and quantitative information about vaccine components and host immune responses, making it a fundamental technology in vaccine science. Although new and more advanced immunoassay platforms are emerging, the reliability, cost-effectiveness, and adaptability to high-throughput systems of ELISA ensure its continued prominence.
Reference
